Clinical Trial Update: Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of lebrikizumab in adolescents with moderate-to-severe atopic dermatitis has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2023-02-24